Sixty Years of CA: A Cancer Journal for Clinicians

  title={Sixty Years of CA: A Cancer Journal for Clinicians},
  author={Ted Gansler and Patricia A. Ganz and Maurice Grant and Frederick L Greene and Prudence Johnstone and Mary Mahoney and Lisa A Newman and W. Oh and C. R. Thomas and Michael J. Thun and Andrew Julian Vickers and Richard C Wender and Otis W. Brawley},
  journal={CA: A Cancer Journal for Clinicians},
The first issue of CA: A Cancer Journal for Clinicians was published in November of 1950. On the 60th anniversary of that date, we briefly review several seminal contributions to oncology and cancer control published in our journal during its first decade. CA Cancer J Clin 2010. © 2010 American Cancer Society, Inc. 
A note from history: Landmarks in history of cancer, Part 6
Although more advances were made in the detection, diagnosis, and treatment of cancers than any other period in history, the overall mortality rate of patients with cancer remained high and unchanged.
Original Article Prognostic significance of interleukin 17 in cancer: a meta-analysis
A systematic review and meta-analysis showed that IL-17 has the potential to become a novel prognostic marker in HCC, NSCLC and ESCC and could potentially help to monitor patients' prognosis and assess therapeutic efficacy in clinical treatment.
Prognostic significance of interleukin 17 in cancer: a meta-analysis.
  • X. Zhang, W. Weng, F. Sun
  • Biology, Medicine
    International journal of clinical and experimental medicine
  • 2014
A meta-analysis showed that IL-17 has the potential to become a novel prognostic marker in HCC, NSCLC and ESCC, and could potentially help to monitor patients' prognosis and assess therapeutic efficacy in clinical treatment.
Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer
CN is upregulated in ovarian cancer tissues with later-stage and that the expression of CN, CA72–4, and CEA was remarkably associated with poor prognosis in unique subtype of ovarian cancer.
[Researche advances on CIK cells and their clinical use in lung cancer].
The basic features and mechanism of CIK cells briefly are introduced, the researches ofCIK cells used in the clinical therapy for lung cancer are summarized and several problems that should be addressed before CIK Cells are widely applied to clinical patients are discussed.
Up-regulated Nrf 2 in colorectal carcinoma and predicts poor prognosis
It was found that the expressions of Nrf2, Prdx6 and SOD2 proteins were higher in CRC tissues than in the adjacent non-neoplastic tissues, which resulted in poorer 5-year overall survival outcomes.
Diagnostic value of RASSF1A hypermethylation in colorectal cancer: a meta-analysis.
Bone Profiling Breast Cancer Patients at Parirenyatwa Radiotherapy Clinic, Zimbabwe
Serum bone profile suggests that bone profiles could be a simple tool for assessing prognosis in breast cancer patients, though further research is needed in this setting.
High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer.
PFTK1 may be a potential anticancer target and prognostic marker in patients with CRC, and Kaplan‑Meier OS rate and Cox regression analysis revealed that high P FTK1 expression level was an independent prognostic factor of CRC patients.
Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer
Diagnostic performance of FDG PET/CT was better than MRI for detecting metastatic lymph nodes in patients with endometrial cancer both by patient basis and lesion basis analyses.


American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer
An update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical neoplasia and cancer, based on recommendations from a formal review and recent
American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors
Recommendations on the use of prophylactic HPV vaccines, including who should be vaccinated and at what age, as well as a summary of policy and implementation issues, and implications for screening are discussed.
Screening for cervical cancer: recommendations and rationale.
The USPSTF concludes that the benefits of screening substantially outweigh potential harms and the optimal starting and stopping age and interval for screening is limited.
A statement on lung cancer
To date the American Cancer Society has awarded over 3.4 million dollars in grants for research on lung cancer since 1954. The large-scale follow-up study carried out by its own staff would have cost
Tobacco and lung cancer
Although the reported studies on this subject all find some relationship between smoking and lung cancer, they disagree so markedly in their measure ment of the size of that relationship as to preclude the possibility that ran dom variability is responsible for the differences.
Early diagnosis and cancer cure rates
The present writer is of the opinion that no valid evidence has been presented that should lead one to accept either of the two extremes of the early-diagnosis theory, and that early diagnosis can practically solve the cancer problem, at least for most sites of the disease.
The value of exfoliative cytology in the diagnosis and control of neoplastic disease of the breast
Improved results permit a more opti mistic view of the practicability of utiliz ing the cytological method in mass screen ing for the detection of incipient carci noma of the breast.
Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening
The current ACS guidelines and recent issues are summarized, updates of guidelines for testing for early breast cancer detection by the US Preventive Services Task Force and for prevention and early detection of cervical cancer from the American College of Obstetricians and Gynecologists are addressed, and the most recent data from the National Health Interview Survey pertaining to participation rates in cancer screening are described.
Systemic therapy.
  • A. Wolff
  • Medicine
    Current opinion in oncology
  • 2002
A long overdue revision of the breast cancer staging system becomes effective in January 2003, bringing it more in line with current standards of care and facilitating data collection for future outcome analysis of therapeutic interventions.
Present status and future trends of exfoliative cytology
It is only in the last ten years that exfoliative cytology, particularly as applied in the diagnosis of cancer, has received a wide acceptance by the medical profession, and its value and immense potentialities in diagnosis and research have been fully appreciated.